B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $125
B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ: KYMR ) with a Buy and raises the price target from $110 to $125.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.